Early immunotherapy improves chances of survival in lung cancer
A study by Central South University in China shows that the timing of immunotherapy has a significant impact on treatment outcomes for advanced small cell lung cancer. The results were published in the journal CANCER of the American Cancer Society.
The researchers studied 397 patients who received the immunotherapy drugs atezolizumab or durvalumab in combination with chemotherapy between May 2019 and October 2023. It was found that patients treated before 3:00 p.m. had significantly longer progression-free survival and overall survival. After accounting for influencing factors, early administration was associated with a 52% lower risk of disease progression and a 63% lower risk of death.
The circadian rhythm, which controls physiological processes such as immune responses, could be the cause of the difference in effectiveness. Study leader Yongchang Zhang emphasizes that adjusting the infusion timing is a cost-effective and easy-to-implement measure that can improve treatment protocols. The results could have immediate clinical relevance for the treatment of small cell lung cancer.
Original paper:
Editor: X-Press Journalistenbüro GbR
Gender Notice. The personal designations used in this text always refer equally to female, male and diverse persons. Double/triple naming and gendered designations are used for better readability. ected.
Most read
World’s first shunt operation with microsurgical robotic system at the UKSH At the University Medical Center Schleswig-Holstein (UKSH), Kiel Campus, a shunt operation was perfo...- MEDICA 2025 and COMPAMED 2025 start in Düsseldorf As of today, the Düsseldorf Exhibition Centre will become the centre of the international healthcare...
- ASKED: “We get excellent feedback on our graduates†The Albstadt-Sigmaringen State University of Applied Sciences offers the shortened course of study f...
